Gaur Saumil, Patrick Reeba, Vankalakunti Mahesha, Phadke Kishore
Division of Paediatric Nephrology, Rainbow Children's Hospital, Marathahalli, Bangalore, Karnataka, India.
Department of Pathology, Manipal Hospitals, Old Airport Road, Bangalore, Karnataka, India.
Indian J Nephrol. 2022 Jan-Feb;32(1):54-59. doi: 10.4103/ijn.IJN_578_20. Epub 2021 Nov 13.
There is a paucity of clinical data on C1q nephropathy (C1qN) in children in India and Southeast Asia. This is the first detailed analysis conducted to elucidate the prevalence, clinicopathological profile, and response to different immunosuppressives in children with C1qN in India.
Detailed demographic profile, clinical features, urine and blood chemistries, kidney biopsy, and response to different immunosuppressives of the study participants were analyzed between August 2015 and October 2020 for steroid-dependent/-resistant nephrotic syndrome (NS).
C1qN was diagnosed in 16 (14.13%) of 113 children who underwent biopsy for steroid-dependent/-resistant NS. The mean age was 44 months (range 18-99 months) and male and female number was 12 (75%) and four (25%), respectively, and mean follow-up was 3.5 years. Eight (50%) had coexistent minimal-change nephrotic syndrome (MCNS) pattern, seven (43.7%) had focal segmental glomerulosclerosis (FSGS), and one (6.2%) had diffuse mesangial hypercellularity. Thirteen children had complete follow-up, of which eight (61.5%) and four (30.7%) cases presented as steroid-dependent and primary steroid-resistant NS, respectively, whereas one (7.6%) had joint pain with rashes. At presentation, seven (53.8%) had hypertension, 12 (92.3%) had nephrotic range proteinuria, and six cases (46.1%) had hematuria. Nine (75%) of 12 cases achieved complete remission with calcineurin inhibitor (CNI) therapy, and two were non responders, one was a partial responder, and one responded to mycophenolate. Of six FSGS cases, four had complete remission, one had partial remission, and one was in non-remission. Of six cases with MCNS, five had complete remission and one was in non-remission. Renal functions remained normal in all except one case who had progression to chronic kidney disease Stage 3.
One out of seven children with difficult NS can have underlying C1qN. CNIs are most beneficial to attain and maintain remission. Renal functions remain normal in the majority. Along with C1q deposits, MCNS and FSGS patterns are seen equally and respond almost similarly to CNIs.
在印度和东南亚,关于儿童C1q肾病(C1qN)的临床数据匮乏。这是首次对印度C1qN患儿的患病率、临床病理特征以及对不同免疫抑制剂的反应进行的详细分析。
对2015年8月至2020年10月间因激素依赖/抵抗型肾病综合征(NS)接受活检的研究参与者的详细人口统计学资料、临床特征、尿液和血液化学指标、肾活检以及对不同免疫抑制剂的反应进行分析。
在113例因激素依赖/抵抗型NS接受活检的儿童中,16例(14.13%)被诊断为C1qN。平均年龄为44个月(范围18 - 99个月),男性12例(75%),女性4例(25%),平均随访时间为3.5年。8例(50%)同时存在微小病变肾病综合征(MCNS)模式,7例(43.7%)有局灶节段性肾小球硬化(FSGS),1例(6.2%)有弥漫性系膜细胞增多。13例患儿有完整随访,其中分别有8例(61.5%)和4例(30.7%)表现为激素依赖型和原发性激素抵抗型NS,而1例(7.6%)有关节疼痛伴皮疹。就诊时,7例(53.8%)有高血压,12例(92.3%)有肾病范围蛋白尿,6例(46.1%)有血尿。12例中的9例(75%)接受钙调神经磷酸酶抑制剂(CNI)治疗后完全缓解,2例无反应,1例部分缓解,1例对霉酚酸酯有反应。6例FSGS病例中,4例完全缓解,1例部分缓解,1例未缓解。6例MCNS病例中,5例完全缓解,1例未缓解。除1例进展为慢性肾脏病3期外,所有患儿的肾功能均保持正常。
7例难治性NS患儿中1例可能存在潜在的C1qN。CNI对实现和维持缓解最为有益。大多数患儿的肾功能保持正常。除C1q沉积外,MCNS和FSGS模式同样可见,且对CNI的反应几乎相似。